Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Veterinary Diagnostic Investigation

• Publication date

  2018-04-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/1040638718770239PMID 29629647PMCID PMC6505918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis

  2015cited by this paper
• Translational biology of osteosarcoma

  2014cited by this paper
• Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.

  2014cited by this paper
• p53 mutations in cancer

  2013cited by this paper
• Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B

  2013cited by this paper
• Immunohistochemical investigation of cell cycle and apoptosis regulators (Survivin, β-Catenin, P53, Caspase 3) in canine appendicular osteosarcoma

  2012cited by this paper
• Dog models of naturally occurring cancer.

  2011cited by this paper
• Characterization of canine osteosarcoma by array comparative genomic hybridization and RT‐qPCR: Signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart

  2011cited by this paper
• Influence of different decalcifying agents on EGF and EGFR immunostaining.

  2011cited by this paper
• A Role for the Retinoblastoma Protein As a Regulator of Mouse Osteoblast Cell Adhesion: Implications for Osteogenesis and Osteosarcoma Formation

  2010cited by this paper
• Influence of genetic background on tumor karyotypes: Evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma

  2009cited by this paper
• PTEN and the PI3-kinase pathway in cancer.

  2009cited by this paper
• Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage

  2008cited by this paper
• Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation

  2008cited by this paper
• The nuclear affairs of PTEN

  2008cited by this paper
• TP53 gene mutations in canine osteosarcoma.

  2008cited by this paper
• Essential role for nuclear PTEN in maintaining chromosomal integrity.

  2007cited by this paper
• PTEN enters the nuclear age.

  2007cited by this paper
• Nuclear PTEN: a tale of many tails

  2007cited by this paper
• Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells.

  2006cited by this paper
• Nucleocytoplasmic Shuttling of the Retinoblastoma Tumor Suppressor Protein via Cdk Phosphorylation-dependent Nuclear Export*

  2006cited by this paper
• TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.

  2005cited by this paper
• Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis.

  2005cited by this paper
• Tumor Suppressor PTEN is Mutated in Canine Osteosarcoma Cell Lines and Tumors

  2002cited by this paper
• Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma

  2002cited by this paper
• Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma

  2001cited by this paper
• Inactivation of p53 and Retinoblastoma Family Pathways in Canine Osteosarcoma Cell Lines

  2000cited by this paper
• Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog.

  1998cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• p53 Tumor Suppressor Protein Overexpression in Osteogenic Tumors of Dogs

  1996cited by this paper
• Distinct sub‐populations of the retinoblastoma protein show a distinct pattern of phosphorylation.

  1994cited by this paper
• The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing

  1994cited by this paper
• The retinoblastoma gene product is bound in the nucleus in early G1 phase.

  1993cited by this paper
• A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity

  1993cited by this paper
• G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment.

  1991cited by this paper
• Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level.

  1991cited by this paper
• Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

  1988cited by this paper
• Effect of decalcification agents on immunoreactivity of cellular antigens.

  1987cited by this paper

• Association between ultraviolet-related TP53 mutations and immune microenvironment in equine ocular squamous cell carcinoma.

  2026cites this paper
• Establishment and characterization of canine mammary tumors 622: A novel luminal B CMT cell line exhibiting partial epithelial–mesenchymal transition and intermediate drug sensitivity

  2025cites this paper
• Targeting mechanotransduction in osteosarcoma.

  2025cites this paper
• Expression of mPGES1 and p16 in feline and human oral squamous cell carcinoma: A comparative oncology approach.

  2024cites this paper
• Predictive value of TP53 RNAscope®in situ hybridization and p53 immunohistochemistry for TP53 mutational status in canine diffuse large B-cell lymphoma

  2024cites this paper
• Immunohistochemical Expression of PTEN in Canine Gliomas

  2024cites this paper
• Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis

  2023cites this paper
• Isolation and Characterization of Novel Canine Osteosarcoma Cell Lines from Chemotherapy-Naïve Patients

  2023cites this paper
• The second-generation curcumin analogue RL71 elicits G2/M cell cycle arrest and apoptosis in canine osteosarcoma cells.

  2023cites this paper
• Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma

  2023cites this paper
• Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma

  2022cites this paper
• Protein Expression of PI3K/AKT/mTOR Pathway Targets Validated by Gene Expression and its Correlation with Prognosis in Canine Mammary Cancer

  2022cites this paper
• Immunohistochemical expression of proliferation markers in canine osteosarcoma

  2022cites this paper
• Recent Advances in the Discovery of Biomarkers for Canine Osteosarcoma

  2021cites this paper
• DNA damage response proteins in canine cancer as potential research targets in comparative oncology

  2021cites this paper
• An Immunohistochemical Study of the PTEN/AKT Pathway Involvement in Canine and Feline Mammary Tumors

  2021cites this paper
• p53, ER, and Ki67 Expression in Canine Mammary Carcinomas and Correlation With Pathological Variables and Prognosis

  2020cites this paper
• Expression of Hematopoietic Stem and Endothelial Cell Markers in Canine Hemangiosarcoma

  2020cites this paper
• Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

  2020cites this paper
• Characterization of D-17 Canine Osteosarcoma Cell Line and Evaluation of Its Ability to Response to Infective Stressor Used as Alternative Anticancer Therapy

  2020cites this paper